Literature DB >> 17117028

Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome.

Wan Beom Park1, Pyoeng Gyun Choe, Jae Hyun Jo, Sung-Han Kim, Ji Hwan Bang, Hong Bin Kim, Nam Joong Kim, Myoung-Don Oh, Kang Won Choe.   

Abstract

Little is known about the effect of immune reconstitution inflammatory syndrome (IRIS) on the long-term clinical outcome. Of 52 opportunistic infections (OI) occurring within one year after the start of HAART in 387 HIV patients, 33 (63%) were classified as having IRIS. The patients with IRIS showed no significant difference in the AIDS event-free survival curve compared with the matched control group without OI and in contrast to non-IRIS OI.

Entities:  

Mesh：

Year:  2006        PMID： 17117028     DOI： 10.1097/QAD.0b013e328010f201

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  10 in total

1.  Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors:  Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

2.  Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.

Authors:  Paul E Sax; Caroline E Sloan; Bruce R Schackman; Philip M Grant; Jian Rong; Andrew R Zolopa; William Powderly; Elena Losina; Kenneth A Freedberg
Journal:  HIV Clin Trials       Date:  2010 Sep-Oct

3.  Immune reconstitution inflammatory syndrome: incidence and implications for mortality.

Authors:  Richard M Novak; James T Richardson; Kate Buchacz; Joan S Chmiel; Marcus D Durham; Frank J Palella; Andrea Wendrow; Kathy Wood; Benjamin Young; John T Brooks
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

4.  Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.

Authors:  Philip M Grant; Lauren Komarow; Janet Andersen; Irini Sereti; Savita Pahwa; Michael M Lederman; Joseph Eron; Ian Sanne; William Powderly; Evelyn Hogg; Carol Suckow; Andrew Zolopa
Journal:  PLoS One       Date:  2010-07-01       Impact factor: 3.240

Review 5.  Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.

Authors:  Philip Grant; Andrew Zolopa
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

6.  Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164.

Authors:  Philip M Grant; Lauren Komarow; Michael M Lederman; Savita Pahwa; Andrew R Zolopa; Janet Andersen; David M Asmuth; Sridevi Devaraj; Richard B Pollard; Aaron Richterman; Sudheesh Kanthikeel; Irini Sereti
Journal:  J Infect Dis       Date:  2012-09-21       Impact factor: 5.226

7.  [Acute renal failure and hypercalcemia in an AIDS patient on tenofovir and low-dose vitamin D therapy with immune reconstitution inflammatory syndrome].

Authors:  Mahyar Lavae-Mokhtari; Somayeh Mohammad-Khani; Reinhold Ernst Schmidt; Matthias Stoll
Journal:  Med Klin (Munich)       Date:  2009-10-25

8.  Disseminated infections due to Immune Reconstitution Inflammatory Syndrome after highly active antiretroviral therapy--report of 3 cases from Nigeria.

Authors:  Dimie Ogoina; Victor Adekunle; Reginald Obiako; Abdulaziz Umar; Michael Akolawole; Joseph Ovosi
Journal:  Pan Afr Med J       Date:  2011-08-16

9.  Extracorporeal life support for immune reconstitution inflammatory syndrome in HIV patients with Pneumocystis jirovecii pneumonia.

Authors:  Kollengode Ramanathan; Julian K Svasti; Graeme MacLaren
Journal:  J Artif Organs       Date:  2018-03-24       Impact factor: 1.731

10.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.